Policy 15: Policy on publications by EMA staff and EMA scientific committee members on EMA’s work
Agenda - SPOR & XEVMPD status update webinar - 22 January 2025
Annex IV questions and answers – Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices
Annex III questions and answers – Annual fees and remuneration
Annex II questions and answers – Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products
Annex I questions and answers – Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use
New fee regulation working arrangements
CHMP PROM minutes for the meeting on 02 December 2024
Human medicines European public assessment report (EPAR): Ocaliva, obeticholic acid, Date of authorisation: 12/12/2016, Revision: 21, Status: Revoked
PSUSA/00010665/202405